LYKALABS

LYKA LABS

Small Cap BSE: 500259 NSE: LYKALABS
₹133.8
-3.4 (-2.48%)
As on 10 December, 2022 | 08:50

Lyka Labs Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in LYKA LABS

Start SIP

Lyka Labs Share Price

Lyka Labs Share Returns

  • Over 1 Month 3.72%
  • Over 3 Month -8.45%
  • Over 6 Month 6.87%
  • Over 1 Year -22.95%

Lyka Labs Key Statistics

P/E Ratio -43.8
PEG Ratio 0.4
Market Cap Cr 384
Price to Book Ratio 28.5
EPS
Dividend 0
Relative Strength Index 50.15
Money Flow Index 75.78
MACD Signal 1.02
Average True Range 6.71

Lyka Labs Investment Rating

  • Master Rating:
  • Lyka Labs has an operating revenue of Rs. 123.78 Cr. on a trailing 12-month basis. An annual revenue growth of 123% is outstanding, Pre-tax margin of 31% is great, ROE of 292% is exceptional. The company has a high debt to equity of 463%, which can be a reason to worry. The stock from a technical standpoint is trading close to its key moving averages, around 4% and 0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 9 which is a GOOD score indicating consistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lyka Labs Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 22222828654318
Operating Expenses Qtr Cr 17161616211412
Operating Profit Qtr Cr 56121244305
Depreciation Qtr Cr 3392222
Interest Qtr Cr 3335676
Tax Qtr Cr 0013062-4
Net Profit Qtr Cr 00-15630200

Lyka Labs Technicals

EMA & SMA

Current Price
133.8
-3.4 (-2.48%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 134.11
  • 50 Day
  • 133.25
  • 100 Day
  • 133.72
  • 200 Day
  • 132.92
  • 20 Day
  • 132.06
  • 50 Day
  • 132.06
  • 100 Day
  • 133.19
  • 200 Day
  • 136.09

Lyka Labs Resistance and Support

PIVOT
₹135.9
Resistance
First Resistance 140.2
Second Resistance 143.2
Third Resistance 147.5
RSI 50.15
MFI 75.78
MACD Single Line 1.02
MACD 1.21
Support
First Resistance 132.9
Second Resistance 128.6
Third Resistance 125.6

Lyka Labs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 172,902 5,840,630 33.78
Week 86,798 3,866,833 44.55
1 Month 140,307 7,013,942 49.99
6 Month 185,616 9,076,626 48.9

Lyka Labs Result Highlights

Lyka Labs Synopsis

NSE-Medical-Generic Drugs

Lyka Labs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 164.35 Cr. and Equity Capital is Rs. 28.69 Cr. for the Year ended 31/03/2022. Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738.
Market Cap 384
Sales 100
Shares in Float 1.49
No of funds 18
Yield
Book Value 8.64
U/D Vol ratio 1.2
LTDebt / Equity 137
Alpha -0.08
Beta 1.03

Lyka Labs

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 47.59%47.8%47.79%
Mutual Funds 3.54%3.54%0.73%
Insurance Companies 0.46%0.46%0.46%
Foreign Portfolio Investors 0.57%0.76%1.12%
Financial Institutions/ Banks
Individual Investors 37.72%38.85%37.26%
Others 10.12%8.59%12.64%

Lyka Labs Management

Name Designation
Mr. Kunal N Gandhi Chairman & M.D & CEO
Mr. Yogesh B Shah Executive Director & CFO
Mrs. Nehal N Gandhi Non Executive Director
Mr. Vinod S Shanbhag Independent Director
Mr. Sandeep P Parikh Independent Director
Mrs. Dhara P Shah Independent Director

Lyka Labs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Lyka Labs Corporate Action

Date Purpose Remarks
2022-11-09 Quarterly Results
2022-08-08 Quarterly Results & Amalgamation
2022-05-20 Audited Results
2022-01-20 Quarterly Results
2021-10-29 Quarterly Results

Lyka Labs MF Shareholding

Name Amount(cr)
Quant Active Fund Growth 3221
Quant Value Fund Regular Growth 553

Lyka Labs FAQs

What is Share Price of Lyka Labs ?

Lyka Labs share price is ₹133 As on 10 December, 2022 | 08:36

What is the Market Cap of Lyka Labs ?

The Market Cap of Lyka Labs is ₹383.9 Cr As on 10 December, 2022 | 08:36

What is the P/E ratio of Lyka Labs ?

The P/E ratio of Lyka Labs is -43.8 As on 10 December, 2022 | 08:36

What is the PB ratio of Lyka Labs ?

The PB ratio of Lyka Labs is 28.5 As on 10 December, 2022 | 08:36

Q2FY23